Literature DB >> 2843685

Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems.

E Littler1, J R Arrand.   

Abstract

The establishment of mammalian and procaryotic systems which express the Epstein-Barr virus (EBV) thymidine kinase (TK) has been reported previously (E. Littler, J. Zeuthen, A. A. McBride, E. Trøst-Sørensen, K. L. Powell, J. E. Walsh-Arrand, and J. R. Arrand, EMBO J. 5:1959-1966, 1986). The EBV TK activity expressed in both of these systems was characterized by in vitro assays and found to resemble that of the herpes simplex virus TK both in its broad range of nucleoside and nucleotide utilization and also in its ability to accept antiviral nucleoside analogs as substrates. Further results are presented which suggest that these in vitro systems may prove suitable for studying the potential anti-EBV activity of other candidate antiviral compounds.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2843685      PMCID： PMC253540          DOI： 10.1128/JVI.62.10.3892-3895.1988

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  18 in total

1.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1.

Authors:  B A Larder; Y C Cheng; G Darby
Journal:  J Gen Virol       Date:  1983-03       Impact factor: 3.891

3.  Effects of arabinofuranosylthymine on Epstein-Barr virus replication.

Authors:  T Ooka; A Calender
Journal:  Virology       Date:  1980-07-15       Impact factor: 3.616

4.  Induction of thymidine kinase and DNase in varicella-zoster virus-infected cells and kinetic properties of the virus-induced thymidine kinase.

Authors:  Y C Cheng; T Y Tsou; T Hackstadt; L P Mallavia
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

5.  Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus.

Authors:  J C Lin; M C Smith; J S Pagano
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

6.  Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U.

Authors:  M H St Clair; W H Miller; R L Miller; C U Lambe; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

7.  Effect of arabinofuranosylthymine on the replication of Epstein-Barr virus and relationship with a new induced thymidine kinase activity.

Authors:  T Ooka; A Calender; M de Turenne; J Daillie
Journal:  J Virol       Date:  1983-04       Impact factor: 5.103

8.  Comparison of thymidine kinase activities indiced in cells productively infected with herpesvirus saimiri and herpes simplex virus.

Authors:  R W Honess; P O'Hare; D Young
Journal:  J Gen Virol       Date:  1982-02       Impact factor: 3.891

9.  Synthesis of thymidine kinase (TK) in Epstein-Barr virus-superinfected Raji TK-negative cells.

Authors:  J Roubal; G Klein
Journal:  Intervirology       Date:  1981       Impact factor: 1.763

10.  Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl)guanine] in Epstein-Barr virus-infected lymphoblastoid cell lines.

Authors:  B M Colby; P A Furman; J E Shaw; G B Elion; J S Pagano
Journal:  J Virol       Date:  1981-05       Impact factor: 5.103
View more
  10 in total

1.  A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

Authors:  Susan P Perrine; Olivier Hermine; Trudy Small; Felipe Suarez; Richard O'Reilly; Farid Boulad; Joyce Fingeroth; Melissa Askin; Arthur Levy; Steven J Mentzer; Massimo Di Nicola; Alessandro M Gianni; Christoph Klein; Steven Horwitz; Douglas V Faller
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

2.  Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.

Authors:  Natacha Coen; Sophie Duraffour; Dimitri Topalis; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

3.  Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues.

Authors:  S M Moore; J S Cannon; Y C Tanhehco; F M Hamzeh; R F Ambinder
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.

Authors:  Qiao Meng; Stacy R Hagemeier; Joyce D Fingeroth; Edward Gershburg; Joseph S Pagano; Shannon C Kenney
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

5.  KSHV-TK is a tyrosine kinase that disrupts focal adhesions and induces Rho-mediated cell contraction.

Authors:  Michael B Gill; Rachel Turner; Philip G Stevenson; Michael Way
Journal:  EMBO J       Date:  2014-12-03       Impact factor: 11.598

6.  The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.

Authors:  E A Gustafson; A C Chillemi; D R Sage; J D Fingeroth
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Identification and characterization of the conserved nucleoside-binding sites in the Epstein-Barr virus thymidine kinase.

Authors:  Chung-Chun Wu; Min-Che Chen; Ya-Ru Chang; Tsuey-Ying Hsu; Jen-Yang Chen
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

8.  Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.

Authors:  Wen-hai Feng; Eva Westphal; Amy Mauser; Nancy Raab-Traub; Margaret L Gulley; Pierre Busson; Shannon C Kenney
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

9.  Activity of penciclovir against Epstein-Barr virus.

Authors:  T H Bacon; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

10.  Quaternary structure of vaccinia virus thymidine kinase.

Authors:  M E Black; D E Hruby
Journal:  Biochem Biophys Res Commun       Date:  1990-06-29       Impact factor: 3.322
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.